Trial Profile
A Phase II Trial of Dasatinib in KIT-Positive Patients With Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 23 Feb 2021 Status changed from discontinued to completed.
- 23 Oct 2020 Planned End Date changed from 6 Aug 2020 to 28 Dec 2020.
- 11 Feb 2020 Planned End Date changed from 6 May 2021 to 6 Aug 2020.